Prolonged human neural stem cell maturation supports recovery in injured rodent CNS

Paul Lu, Steven Ceto, Yaozhi Wang, Lori Graham, Di Wu, Hiromi Kumamaru, Eileen Staufenberg, Mark H. Tuszynski

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Neural stem cells (NSCs) differentiate into both neurons and glia, and strategies using human NSCs have the potential to restore function following spinal cord injury (SCI). However, the time period of maturation for human NSCs in adult injured CNS is not well defined, posing fundamental questions about the design and implementation of NSC-based therapies. This work assessed human H9 NSCs that were implanted into sites of SCI in immunodeficient rats over a period of 1.5 years. Notably, grafts showed evidence of continued maturation over the entire assessment period. Markers of neuronal maturity were first expressed 3 months after grafting. However, neurogenesis, neuronal pruning, and neuronal enlargement continued over the next year, while total graft size remained stable over time. Axons emerged early from grafts in very high numbers, and half of these projections persisted by 1.5 years. Mature astrocyte markers first appeared after 6 months, while more mature oligodendrocyte markers were not present until 1 year after grafting. Astrocytes slowly migrated from grafts. Notably, functional recovery began more than 1 year after grafting. Thus, human NSCs retain an intrinsic human rate of maturation, despite implantation into the injured rodent spinal cord, yet they support delayed functional recovery, a finding of great importance in planning human clinical trials. ENGL.

Original languageEnglish
Pages (from-to)3287-3299
Number of pages13
JournalJournal of Clinical Investigation
Volume127
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Neural Stem Cells
Rodentia
Transplants
Spinal Cord Injuries
Astrocytes
Neuronal Plasticity
Neurogenesis
Oligodendroglia
Cell- and Tissue-Based Therapy
Neuroglia
Axons
Spinal Cord
Clinical Trials
Neurons

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Prolonged human neural stem cell maturation supports recovery in injured rodent CNS. / Lu, Paul; Ceto, Steven; Wang, Yaozhi; Graham, Lori; Wu, Di; Kumamaru, Hiromi; Staufenberg, Eileen; Tuszynski, Mark H.

In: Journal of Clinical Investigation, Vol. 127, No. 9, 01.09.2017, p. 3287-3299.

Research output: Contribution to journalArticle

Lu, P, Ceto, S, Wang, Y, Graham, L, Wu, D, Kumamaru, H, Staufenberg, E & Tuszynski, MH 2017, 'Prolonged human neural stem cell maturation supports recovery in injured rodent CNS', Journal of Clinical Investigation, vol. 127, no. 9, pp. 3287-3299. https://doi.org/10.1172/JCI92955
Lu, Paul ; Ceto, Steven ; Wang, Yaozhi ; Graham, Lori ; Wu, Di ; Kumamaru, Hiromi ; Staufenberg, Eileen ; Tuszynski, Mark H. / Prolonged human neural stem cell maturation supports recovery in injured rodent CNS. In: Journal of Clinical Investigation. 2017 ; Vol. 127, No. 9. pp. 3287-3299.
@article{28cd032007a04735a1b66a69997cd9f5,
title = "Prolonged human neural stem cell maturation supports recovery in injured rodent CNS",
abstract = "Neural stem cells (NSCs) differentiate into both neurons and glia, and strategies using human NSCs have the potential to restore function following spinal cord injury (SCI). However, the time period of maturation for human NSCs in adult injured CNS is not well defined, posing fundamental questions about the design and implementation of NSC-based therapies. This work assessed human H9 NSCs that were implanted into sites of SCI in immunodeficient rats over a period of 1.5 years. Notably, grafts showed evidence of continued maturation over the entire assessment period. Markers of neuronal maturity were first expressed 3 months after grafting. However, neurogenesis, neuronal pruning, and neuronal enlargement continued over the next year, while total graft size remained stable over time. Axons emerged early from grafts in very high numbers, and half of these projections persisted by 1.5 years. Mature astrocyte markers first appeared after 6 months, while more mature oligodendrocyte markers were not present until 1 year after grafting. Astrocytes slowly migrated from grafts. Notably, functional recovery began more than 1 year after grafting. Thus, human NSCs retain an intrinsic human rate of maturation, despite implantation into the injured rodent spinal cord, yet they support delayed functional recovery, a finding of great importance in planning human clinical trials. ENGL.",
author = "Paul Lu and Steven Ceto and Yaozhi Wang and Lori Graham and Di Wu and Hiromi Kumamaru and Eileen Staufenberg and Tuszynski, {Mark H.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1172/JCI92955",
language = "English",
volume = "127",
pages = "3287--3299",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - Prolonged human neural stem cell maturation supports recovery in injured rodent CNS

AU - Lu, Paul

AU - Ceto, Steven

AU - Wang, Yaozhi

AU - Graham, Lori

AU - Wu, Di

AU - Kumamaru, Hiromi

AU - Staufenberg, Eileen

AU - Tuszynski, Mark H.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Neural stem cells (NSCs) differentiate into both neurons and glia, and strategies using human NSCs have the potential to restore function following spinal cord injury (SCI). However, the time period of maturation for human NSCs in adult injured CNS is not well defined, posing fundamental questions about the design and implementation of NSC-based therapies. This work assessed human H9 NSCs that were implanted into sites of SCI in immunodeficient rats over a period of 1.5 years. Notably, grafts showed evidence of continued maturation over the entire assessment period. Markers of neuronal maturity were first expressed 3 months after grafting. However, neurogenesis, neuronal pruning, and neuronal enlargement continued over the next year, while total graft size remained stable over time. Axons emerged early from grafts in very high numbers, and half of these projections persisted by 1.5 years. Mature astrocyte markers first appeared after 6 months, while more mature oligodendrocyte markers were not present until 1 year after grafting. Astrocytes slowly migrated from grafts. Notably, functional recovery began more than 1 year after grafting. Thus, human NSCs retain an intrinsic human rate of maturation, despite implantation into the injured rodent spinal cord, yet they support delayed functional recovery, a finding of great importance in planning human clinical trials. ENGL.

AB - Neural stem cells (NSCs) differentiate into both neurons and glia, and strategies using human NSCs have the potential to restore function following spinal cord injury (SCI). However, the time period of maturation for human NSCs in adult injured CNS is not well defined, posing fundamental questions about the design and implementation of NSC-based therapies. This work assessed human H9 NSCs that were implanted into sites of SCI in immunodeficient rats over a period of 1.5 years. Notably, grafts showed evidence of continued maturation over the entire assessment period. Markers of neuronal maturity were first expressed 3 months after grafting. However, neurogenesis, neuronal pruning, and neuronal enlargement continued over the next year, while total graft size remained stable over time. Axons emerged early from grafts in very high numbers, and half of these projections persisted by 1.5 years. Mature astrocyte markers first appeared after 6 months, while more mature oligodendrocyte markers were not present until 1 year after grafting. Astrocytes slowly migrated from grafts. Notably, functional recovery began more than 1 year after grafting. Thus, human NSCs retain an intrinsic human rate of maturation, despite implantation into the injured rodent spinal cord, yet they support delayed functional recovery, a finding of great importance in planning human clinical trials. ENGL.

UR - http://www.scopus.com/inward/record.url?scp=85028924759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028924759&partnerID=8YFLogxK

U2 - 10.1172/JCI92955

DO - 10.1172/JCI92955

M3 - Article

C2 - 28825600

AN - SCOPUS:85028924759

VL - 127

SP - 3287

EP - 3299

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -